These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21289145)

  • 41. Performance comparison of an in-house integrase genotyping assay versus the ViroSeq™ Integra48, and study of HIV-1 integrase polymorphisms in Hong Kong.
    To SW; Chen JH; Wong KH; Chan KC; Ng HM; Wu H; Lam JT; Yam WC
    J Clin Virol; 2013 Sep; 58(1):299-302. PubMed ID: 23886504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
    Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
    BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted HIV-1-specific CTL recognition.
    Rahman MA; Kuse N; Murakoshi H; Chikata T; Gatanaga H; Oka S; Takiguchi M
    Microbes Infect; 2014 May; 16(5):434-8. PubMed ID: 24657622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
    AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.
    Armenia D; Fabeni L; Alteri C; Di Pinto D; Di Carlo D; Bertoli A; Gori C; Carta S; Fedele V; Forbici F; D'Arrigo R; Svicher V; Berno G; Pizzi D; Nicastri E; Sarmati L; Pinnetti C; Ammassari A; D'Offizi G; Latini A; Andreoni M; Antinori A; Ceccherini-Silberstein F; Perno CF; Santoro MM
    J Antimicrob Chemother; 2015; 70(6):1865-73. PubMed ID: 25712318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Boeri E; Spagnuolo V; Cossarini F; Castagna A; Lazzarin A; Clementi M
    J Infect Dis; 2011 Dec; 204(11):1811-5. PubMed ID: 21984737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low cost HIV-1 quantitative RT-PCR assay in resource-limited settings: improvement and implementation.
    Fibriani A; Farah N; Kusumadewi I; Pas SD; van Crevel R; van der Ven A; Boucher CA; Schutten M
    J Virol Methods; 2012 Oct; 185(1):118-23. PubMed ID: 22766178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
    Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
    Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
    Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations.
    Nguyen TT; Rato S; Molina JM; Clavel F; Delaugerre C; Mammano F
    J Antimicrob Chemother; 2015 Mar; 70(3):731-8. PubMed ID: 25336162
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
    Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
    J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abbott RealTime HIV-1 m2000rt viral load testing: manual extraction versus the automated m2000sp extraction.
    Scott LE; Crump JA; Msuya E; Morrissey AB; Venter WF; Stevens WS
    J Virol Methods; 2011 Mar; 172(1-2):78-80. PubMed ID: 21172389
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV-1 viral load measurement in venous blood and fingerprick blood using Abbott RealTime HIV-1 DBS assay.
    Tang N; Pahalawatta V; Frank A; Bagley Z; Viana R; Lampinen J; Leckie G; Huang S; Abravaya K; Wallis CL
    J Clin Virol; 2017 Jul; 92():56-61. PubMed ID: 28531553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The first B/G intersubtype recombinant form of human immunodeficiency virus type 1 (HIV-1) identified in Germany was undetected or underquantitated by some commercial viral load assays.
    von Truchsess I; Harris B; Schätzl HM; Hackett J
    J Med Virol; 2006 Mar; 78(3):311-7. PubMed ID: 16419111
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
    Roquebert B; Damond F; Collin G; Matheron S; Peytavin G; Bénard A; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    J Antimicrob Chemother; 2008 Nov; 62(5):914-20. PubMed ID: 18718922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the bioMérieux NucliSENS EasyQ HIV-1 v2.0-HIV-1 RNA quantification assay versus Abbott RealTime HIV-1 and Roche Cobas TaqMan HIV-1 v2.0 on current epidemic HIV-1 variants.
    Mourez T; Delaugerre C; Vray M; Lemée V; Simon F; Plantier JC
    J Clin Virol; 2015 Oct; 71():76-81. PubMed ID: 26318912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of Performance Characteristics of the Aptima HIV-1 Quant Dx Assay for Detection and Quantitation of Human Immunodeficiency Virus Type 1 in Plasma and Cervicovaginal Lavage Samples.
    Sam SS; Kurpewski JR; Cu-Uvin S; Caliendo AM
    J Clin Microbiol; 2016 Apr; 54(4):1036-41. PubMed ID: 26842702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
    Oliveira M; Mesplède T; Moïsi D; Ibanescu RI; Brenner B; Wainberg MA
    AIDS; 2015 Nov; 29(17):2255-60. PubMed ID: 26372484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative evaluation of the Abbott HIV-1 RealTime™ assay with the Standard Roche COBAS® Amplicor™ HIV-1 Monitor® Test, v1.5 for determining HIV-1 RNA levels in plasma specimens from Pune, India.
    Khopkar P; Mallav V; Chidrawar S; Kulkarni S
    J Virol Methods; 2013 Jul; 191(1):82-7. PubMed ID: 23588214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.